Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (Tables)

v3.21.2
Intangibles, net (Tables)
9 Months Ended
Sep. 30, 2021
Intangibles, net  
Schedule of JMC Intangible Asset

The table below provides a summary of the Journey intangible assets as of September 30, 2021 and December 31, 2020, respectively:

Estimated Useful

($ in thousands)

    

Lives (Years)

    

September 30, 2021

    

December 31, 2020

(Unaudited)

Total intangible assets – asset purchases

3 to 7

$

19,003

$

18,606

Accumulated amortization

 

  

 

(5,960)

 

(3,977)

Net intangible assets

 

  

$

13,043

$

14,629

Schedule of JMC recognized expense related to its product licenses

The table below provides a summary for the nine months ended September 30, 2021, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the unaudited condensed consolidated statement of operations:

Intangible

($ in thousands)

    

Assets, Net

Beginning balance at January 1, 2021

$

14,629

Additions:

Exelderm milestone

397

Amortization expense

 

(1,983)

Ending balance at September 30, 2021

$

13,043

Schedule of future amortization of intangible assets

The future amortization of these intangible assets is as follows:

Total

($ in thousands)

    

Ximino®

    

Accutane®

    

Amortization

Three months ending December 31, 2021

$

255

$

236

$

491

Year ended December 31, 2022

 

1,019

 

946

 

1,965

Year ended December 31, 2023

1,019

945

1,964

Year ended December 31, 2024

1,019

946

1,965

Year ended December 31, 2025

 

1,019

 

945

 

1,964

Thereafter

595

157

752

Sub-total

$

4,926

$

4,175

$

9,101

Assets not yet placed in service:

Anti-itch product license acquisition

3,942

Total

$

4,926

$

4,175

$

13,043